VonaONCOLOGY
Early clinical-stage biopharmaceutical company
Our mission is to provide new hope for patients with aggressive cancers.
Vona Oncology develops targeted therapeutics for cancers that have outrun standard treatment — starting with triple-negative breast cancer, ovarian cancer, and melanoma.
Focus
Targeted therapeutics for the cancers that resist them most.
Vona Oncology is an early clinical-stage biopharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer, and melanoma. TNBC is our initial indication for our small molecule drug, VDX-431.
Initial indication
Triple-Negative Breast Cancer
Indication
Ovarian Cancer
Indication
Melanoma
Business summary
Building toward clinical proof, and beyond.
Vona Oncology is focused on the development and commercialization of our lead compound, VDX-431. Our immediate objective is the completion of IND-enabling studies and demonstration of early clinical-phase efficacy in the treatment of TNBC.
Our long-term vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments. Vona Oncology has raised $3.3M in non-dilutive funds to date.
Product
VDX-431
VDX-431 is a small-molecule, well-tolerated drug that will establish a novel class of targeted therapy for the treatment of TNBC, ovarian cancer, and melanoma. Studies from our research team have provided proof-of-concept that VDX-431 is an efficacious therapeutic for all three cancers in pre-clinical cell and animal models.
Compelling pre-clinical data
Strong pre-clinical efficacy across three aggressive cancers.
Cell killing
Our studies have demonstrated strong efficacy of VDX-431 in killing TNBC cells in vitro.
Tumor blockade
VDX-431 blocks TNBC tumor growth in vivo, building on the in vitro evidence of cancer-cell killing.
Path to the clinic
Our ongoing research is focused on IND-enabling studies to advance VDX-431 toward first-in-human clinical trials for TNBC.
Development pipeline
VDX-431 — where we are today.
Our lead compound is advancing through IND-enabling studies for triple-negative breast cancer. Each completed stage builds the evidentiary foundation for first-in-human trials.
Identification
Optimization
In Vitro
In Vivo
Studies
Filing
Clinical Trial
Awards & recognition
Funding from NIH and the State of Colorado.
SBIR Fast Track Grant, supporting the advancement of our lead program toward clinical trials.
Colorado Office of Economic Development and International Trade — Advanced Industry Accelerator Early-Stage Capital Retention Grant.
Disclosures